Jeffes E W, Ahmed A R
Clin Exp Dermatol. 1989 Mar;14(2):132-6. doi: 10.1111/j.1365-2230.1989.tb00910.x.
Thirteen patients with recurrent severe widespread recalcitrant bullous pemphigoid (BP) were studied. These patients had been initially treated with prednisone and azathioprine, and clinically responded. However, they frequently continued to have flare-ups or activation of the disease while still on treatment with high doses of these drugs. The addition of dapsone, as an adjuvant to the treatment, helped to produce a complete clinical remission in 12 patients (92%). In addition, there was a statistically significant difference in the median dose of prednisone, before and after the institution of dapsone, and in the maintenance dose of prednisone. Patients were tapered off prednisone more easily than before and did not flare at lower doses of prednisone as previously. It is suggested that, in patients with severe, recalcitrant, recurrent disease, the addition of dapsone to the existing regime of corticosteroids and/or immunosuppressive drugs, may be beneficial. This may be especially valuable to patients in whom corticosteroids have been used for prolonged periods and in whom increasing the corticosteroid dose further may be associated with significant side-effects.
对13例复发性重度广泛性顽固性大疱性类天疱疮(BP)患者进行了研究。这些患者最初接受泼尼松和硫唑嘌呤治疗,临床有反应。然而,他们在仍接受高剂量这些药物治疗时,疾病仍频繁复发或病情活动。添加氨苯砜作为辅助治疗,帮助12例患者(92%)实现了完全临床缓解。此外,在使用氨苯砜前后,泼尼松的中位剂量以及泼尼松的维持剂量存在统计学显著差异。患者比以前更容易逐渐减少泼尼松用量,且在较低剂量的泼尼松治疗下不再像以前那样病情复发。建议在患有严重、顽固性、复发性疾病的患者中,在现有的皮质类固醇和/或免疫抑制药物治疗方案中添加氨苯砜可能有益。这对于长期使用皮质类固醇且进一步增加皮质类固醇剂量可能会出现明显副作用的患者可能特别有价值。